Tharimmune (NASDAQ:THAR – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($2.02) earnings per share for the quarter, Zacks reports.
Tharimmune Stock Down 2.1 %
THAR traded down $0.03 during trading on Thursday, reaching $1.41. 4,380 shares of the stock were exchanged, compared to its average volume of 64,450. Tharimmune has a 1 year low of $1.28 and a 1 year high of $7.46. The business’s 50 day moving average price is $1.75 and its two-hundred day moving average price is $2.12.
Analyst Ratings Changes
A number of analysts have weighed in on THAR shares. Rodman & Renshaw started coverage on Tharimmune in a research report on Friday, December 6th. They set a “buy” rating and a $17.00 price objective for the company. RODMAN&RENSHAW raised Tharimmune to a “strong-buy” rating in a report on Friday, December 6th.
Tharimmune Company Profile
Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).
Read More
- Five stocks we like better than Tharimmune
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell
- The 3 Best Fintech Stocks to Buy Now
- Top 3 Beverage Stocks Pouring Out Profits
- Why Are These Companies Considered Blue Chips?
- CarMax and Carvana: Steering the Used Car Market
Receive News & Ratings for Tharimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tharimmune and related companies with MarketBeat.com's FREE daily email newsletter.
